Matthew W. Kalnik Insider Trading $VXRT Vaxart, Inc.
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Matthew W. Kalnik.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Matthew W. Kalnik. Matthew W. Kalnik is SVP Strategic Plan. & Bus. Ops in Aviragen Therapeutics, Inc. ($NABI).
Matthew W. Kalnik in Vaxart, Inc.
Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
Position of Matthew W. Kalnik: SVP Strategic Plan. & Bus. Ops
Holdings: 71,050 shares
Current Value: $80,997
Latest Transaction: Apr 05 2011
$VXRT Market Capitalization: $43.28M
$VXRT Previous Close: $1.14
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of Matthew W. Kalnik in Vaxart, Inc.
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 05 2011 | NABI | Aviragen Therapeut ... | Kalnik Matthew W. | SVP Strategic Plan. ... | Option Exercise | A | 5.81 | 75,000 | 435,750 | 75,000 | |
| Apr 05 2011 | NABI | Aviragen Therapeut ... | Kalnik Matthew W. | SVP Strategic Plan. ... | Grant | A | 0.00 | 30,000 | 0 | 71,050 | 41.1 K to 71.1 K (+73.08 %) |
| Apr 05 2011 | NABI | Aviragen Therapeut ... | Kalnik Matthew W. | SVP Strategic Plan. ... | Sell | S | 5.80 | 6,300 | 36,530 | 41,050 | 47.4 K to 41.1 K (-13.31 %) |
| Jul 21 2010 | NABI | Aviragen Therapeut ... | Kalnik Matthew W. | SVP Strategic Plan. ... | Sell | S | 5.48 | 1,625 | 8,905 | 45,725 | 47.4 K to 45.7 K (-3.43 %) |
| Jul 27 2010 | NABI | Aviragen Therapeut ... | Kalnik Matthew W. | SVP Strategic Plan. ... | Sell | S | 5.78 | 1,500 | 8,670 | 44,225 | 45.7 K to 44.2 K (-3.28 %) |
| Apr 15 2010 | NABI | Aviragen Therapeut ... | Kalnik Matthew W. | SVP Strategic Plan. ... | Sell | S | 5.78 | 2,250 | 13,005 | 47,350 | 49.6 K to 47.4 K (-4.54 %) |
| Apr 05 2010 | NABI | Aviragen Therapeut ... | Kalnik Matthew W. | SVP Strategic Plan. ... | Option Exercise | A | 5.49 | 60,000 | 329,400 | 60,000 | |
| Apr 05 2010 | NABI | Aviragen Therapeut ... | Kalnik Matthew W. | SVP Strategic Plan. ... | Sell | W | 5.49 | 2,100 | 11,529 | 49,600 | 51.7 K to 49.6 K (-4.06 %) |
| Apr 05 2010 | NABI | Aviragen Therapeut ... | Kalnik Matthew W. | SVP Strategic Plan. ... | Sell | S | 5.49 | 1,300 | 7,131 | 51,700 | 53 K to 51.7 K (-2.45 %) |
| Apr 05 2010 | NABI | Aviragen Therapeut ... | Kalnik Matthew W. | SVP Strategic Plan. ... | Sell | S | 5.48 | 400 | 2,193 | 53,000 | 53.4 K to 53 K (-0.75 %) |
| Apr 05 2010 | NABI | Aviragen Therapeut ... | Kalnik Matthew W. | SVP Strategic Plan. ... | Sell | S | 5.48 | 250 | 1,370 | 53,400 | 53.7 K to 53.4 K (-0.47 %) |
| Apr 05 2010 | NABI | Aviragen Therapeut ... | Kalnik Matthew W. | SVP Strategic Plan. ... | Grant | A | 0.00 | 24,000 | 0 | 53,650 | 29.7 K to 53.7 K (+80.94 %) |
| Mar 17 2010 | NABI | Aviragen Therapeut ... | Kalnik Matthew W. | SVP Strategic Plan. ... | Sell | S | 5.93 | 9,873 | 58,547 | 29,650 | 39.5 K to 29.7 K (-24.98 %) |
| Mar 17 2010 | NABI | Aviragen Therapeut ... | Kalnik Matthew W. | SVP Strategic Plan. ... | Option Exercise | M | 3.95 | 1,125 | 4,444 | 14,625 | |
| Mar 17 2010 | NABI | Aviragen Therapeut ... | Kalnik Matthew W. | SVP Strategic Plan. ... | Sell | S | 5.95 | 1,125 | 6,694 | 39,523 | 40.6 K to 39.5 K (-2.77 %) |
| Mar 17 2010 | NABI | Aviragen Therapeut ... | Kalnik Matthew W. | SVP Strategic Plan. ... | Buy | M | 3.95 | 1,125 | 4,444 | 40,648 | 39.5 K to 40.6 K (+2.85 %) |
| Mar 04 2010 | NABI | Aviragen Therapeut ... | Kalnik Matthew W. | SVP Strategic Plan. ... | Option Exercise | M | 3.95 | 2,250 | 8,888 | 15,750 | |
| Mar 04 2010 | NABI | Aviragen Therapeut ... | Kalnik Matthew W. | SVP Strategic Plan. ... | Sell | S | 5.45 | 2,250 | 12,263 | 39,523 | 41.8 K to 39.5 K (-5.39 %) |
| Mar 04 2010 | NABI | Aviragen Therapeut ... | Kalnik Matthew W. | SVP Strategic Plan. ... | Buy | M | 3.95 | 2,250 | 8,888 | 41,773 | 39.5 K to 41.8 K (+5.69 %) |
| Mar 04 2010 | NABI | Aviragen Therapeut ... | Kalnik Matthew W. | SVP Strategic Plan. ... | Buy | J | 2.41 | 5,404 | 12,999 | 39,523 | 34.1 K to 39.5 K (+15.84 %) |
| Nov 18 2009 | NABI | Aviragen Therapeut ... | Kalnik Matthew W. | SVP Strategic Plan. ... | Sell | S | 4.97 | 4,900 | 24,353 | 31,119 | 36 K to 31.1 K (-13.60 %) |
| Nov 18 2009 | NABI | Aviragen Therapeut ... | Kalnik Matthew W. | SVP Strategic Plan. ... | Sell | S | 4.97 | 2,000 | 9,942 | 36,019 | 38 K to 36 K (-5.26 %) |
| Nov 18 2009 | NABI | Aviragen Therapeut ... | Kalnik Matthew W. | SVP Strategic Plan. ... | Sell | S | 4.47 | 7,674 | 34,336 | 38,019 | 45.7 K to 38 K (-16.79 %) |
Page: 1